AHA Scientific Sessions 2026 Abstract · Nov 2, 2026

Comparative Efficacy of Nucleic Acid-Based Therapies Targeting Lipoprotein(a): A Network Meta-Analysis

By Olatunji G, BOODGERE SURESH S, Kokori E et al.

Background: Elevated lipoprotein(a) [Lp(a)] is an independent, genetically determined cardiovascular risk factor. Nucleic acid-based agents targeting LPA, including the siRNAs olpasiran, lepodisiran, and zerlasiran, and the antisense oligonucleotide pelacarsen, have demonstrated substantial Lp(a) lowering in phase 2 trials. Research Question: Which nucleic acid-based LPA targeting therapy and dose regimen achieves the greatest Lp(a) reduction, and how do they rank relative to one another in the absence of head-to-head trials? Methods: Four phase 2 randomized placebo-controlled trials were included: OCEAN(a)-DOSE (olpasiran, n=281), ALPACA (lepodisiran, n=320), ALPACAR-360 (zerlasiran, n=178), and AKCEA-APO(a)-LRx (pelacarsen, n=286). Only three monthly (Q4W) pelacarsen arms were included; Q2W and weekly regimens were excluded to maintain dosing interval homogeneity. Comparable dose regimens were selected across studies, yielding 11 active treatment nodes plus placebo and a total analyzed population of 864 participants. A random effects NMA was conducted using placebo as the common comparator. Treatments were ranked using SUCRA-derived scores, with lower values indicating greater efficacy. A sensitivity analysis excluding pelacarsen was performed because standard errors were indirectly derived. Results: All active regimens reduced Lp(a) levels compared with placebo. The largest reductions were observed with olpasiran 225 mg (MD –100.5 mg/dL, 95% CI –105.5 to –95.5), lepodisiran 400 mg (MD –97.6, 95% CI –113.8 to –81.4), and olpasiran 75 mg (MD –97.4, 95% CI –102.5 to –92.3). Zerlasiran also produced substantial reductions (450 mg Q24W: MD –85.6; 300 mg Q24W: MD –81.4). Pelacarsen reductions ranged from –29.0 mg/dL (20 mg Q4W) to –66.0 mg/dL (60 mg Q4W). SUCRA rankings identified olpasiran 225 mg as the highest-ranked regimen (28.1%), followed by lepodisiran 400 mg (29.7%) and olpasiran 75 mg (30.4%). Higher-dose zerlasiran regimens ranked above pelacarsen. Sensitivity analysis rankings were consistent: olpasiran 225 mg (30.4%), lepodisiran 400 mg (32.5%), and olpasiran 75 mg (33.4%). No major inconsistency was identified. Conclusions: Among nucleic acid-based Lp(a)-targeting therapies, olpasiran 225 mg and lepodisiran 400 mg achieved the greatest reductions in Lp(a), each exceeding 97 mg/dL compared with placebo. Higher dose zerlasiran regimens also achieved substantial lowering, whereas monthly pelacarsen produced more modest reductions. Rankings were robust in sensitivity analyses. These findings provide a comparative assessment of phase 2 LPA-targeting therapies and may help inform the design and interpretation of planned and ongoing cardiovascular outcomes trials

doi.org/10.1161/circ.154.suppl_1.14112Interventions

AgingResearch.News